Abstract:Abstract Cancer immunotherapy with 4-1BB agonists faces limited further clinical development due to dose-limiting toxicity. Moreover, EGFR and B7H3 are highly expressed in various solid tumors, as well as in different normal tissues. In this study, we developed a trispecific antibody, KA-3009, targeting EGFR, B7-H3, and human 4-1BB, with the aim of restricting 4-1BB stimulation within tumors. KA-3009 was developed based on our common light chain bispecific antibody discovery platform and nanobody antibody discovery platform using knob-into-hole technology. It is in IgG1 format with mutations in the Fc domain to eliminate ADCC, ADCP, and CDC activity. Featuring two identical nanobodies at the C-terminal against 4-1BB, KA-3009 binds to EGFR and B7H3 respectively with two Fabs at the N-terminal, sharing an identical light chain. KA-3009 exhibits low avidity binding to tumor cells expressing only EGFR or B7H3, while binding to tumor cells co-overexpressing EGFR and B7H3 with increased avidity by more than ten times. Additionally, KA-3009 binds to 4-1BB expressed on 293T cells and activated human T cells. In the presence of a low concentration of CD3 antibody to stimulate T cell activation, co-culture of tumor cells co-expressing EGFR and B7H3 with primary T cells isolated from human PBMC enhances T cell activation and proliferation. In PBMC humanized immunodeficient mouse tumor models, KA-3009 effectively suppresses the growth of NCI-H1568 tumors expressing both EGFR and B7H3 but does not affect the growth of MS751 and NCI-H661 tumors, which only express EGFR or B7H3, respectively. Moreover, KA-3009 has a half-life of more than five days in the blood of Balb/c mice. Finally, we assessed the developability of this antibody with different treatments such as high concentration, low pH, repeated freezing and thawing, and high temperature, and KA-3009 shows neither aggregation nor degradation. In conclusion, the triple-specific antibody KA-3009, developed with our common light chain antibody discovery platform and nanobody antibody discovery platform, is a promising pre-clinical candidate drug for the treatment of different solid cancers that co-overexpress EGFR and B7H3. Citation Format: Guojin Wu, Tongtong Liu, Jiabei Liang, Hao Peng, Feng Hao, Jinying Ning. The triple-specific antibody KA-3009 against EGFR, B7H3, and 4-1BB specifically enhances T cell activity within the tumor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6366.

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer

Agonist antibodies to TNFR molecules that costimulate T and NK cells

An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation

Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization

A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells

Immunotherapy of cancer with 4-1BB

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment

Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors

Abstract 6366: The triple-specific antibody KA-3009 against EGFR, B7H3, and 4-1BB specifically enhances T cell activity within the tumor

A B7-H3-targeted CD28 bispecific antibody enhances the activity of anti-PD1 and CD3 T-cell engager immunotherapies

The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

A trispecific T cell engager CD19xCD3xCD28 induces potent tumor-directed T cell activation and antitumor activity by simultaneously engagement of TCR and a co-stimulatory receptor CD28

4-1BB agonism: adding the accelerator to cancer immunotherapy

Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release